Trump Administration Cuts Moderna Bird Flu Vaccine Funding Amid mRNA Safety Concerns

HHS Cancels Moderna Bird Flu Vaccine Funding

• 💰 The Health and Human Services Department has canceled $766 million in funding for Moderna to develop a bird flu vaccine, a contract awarded during the Biden administration.
• 💡 Moderna had received funding to create vaccines for pandemic flu viruses, including the H5N1 bird flu, and an early trial showed positive results.

Stated Reasons for Cancellation

• ⚠️ HHS Secretary Robert F. Kennedy Jr. has cited deep-seated concerns about the safety of mRNA vaccines as the primary reason for the funding shift.
• 🔬 The department states this cancellation is part of a larger shift away from mRNA vaccine platforms in general.
• 📊 A recent Senate investigation by Republicans into vaccine safety concerns is also cited as a factor.

Expert and Official Perspectives

• 🧑‍⚕️ Experts, federal health officials, and current/former employees have expressed no doubt about the safety of mRNA vaccines, noting they are rigorously tested.
• 🚫 Despite expert consensus, HHS is moving away from funding mRNA vaccines based on cited concerns.

Importance of Bird Flu Vaccine Preparedness

• 🐦 Bird flu viruses have spread from wild birds to cattle in the US, sickening at least 70 people and causing one death.
• 📈 Concerns exist within the medical community about stopping funding if bird flu spreads from person to person.
• 🚀 The original funding was for pandemic preparedness, aiming to ensure the US is first in line for vaccines during an influenza pandemic.
• ⚡ mRNA vaccines are noted for their ability to be quickly adapted to new strains, making them crucial for rapid pandemic response.

Impact on US Vaccine Stockpile

• 📉 The cancellation means the US will not be at the front of the line for early doses of Moderna's bird flu vaccine for its stockpile.
• 🌍 While Moderna receives funding from other countries and its research may continue, the United States will not be a direct funder of this specific vaccine development.